Czech Antibiotics and Biotransformations Research Institute

28 April 1996

- The privatization of the Antibiotics and Biotransformations Research Institute (VUAB) in the Czech Republic is under discussion, with a final decision expected to be taken within two to three months, according to the CTK news agency's Business News. It is possible that the Institute could be partly sold to its management. It was founded in 1949, and is Europe's second-largest manufacturer of ephedrine, producing 150 tonnes a year, according to the report.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight